Retrospective cohort study of resistance associated substitutions and clinical course in Glecaprevir(GLE)/Pibrentasvir(PIB) treatment to hepatitis C virus
Not Applicable
Recruiting
- Conditions
- Hepatitis C virus infected patients
- Registration Number
- JPRN-UMIN000027428
- Lead Sponsor
- Kyoto Prefectural University of Medicine Department of Molecular Gastroenterology and Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 700
Inclusion Criteria
Not provided
Exclusion Criteria
Patients coinfection with human immunodeficiency virus, autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis or Wilson's disease are excluded. Patients with uncontrollable other disease and those with alcohol abuse are also excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The resistance associated substitutions were studied before pre-treatment and non-response or viral breakthrough.
- Secondary Outcome Measures
Name Time Method HCV RNA levels were assessed at pre treatment and 2, 4, 8, 12weeks or end of treatment (EOT) and at 12 and 24 weeks after completion of treatment, and routine biochemical and hematological tests were also performed to evaluate the clinical course.